22 September 2022 in Science
Tissue-specific stem cells persist for a lifetime and can differentiate to maintain homeostasis or transform to initiate cancer. Despite their importance, there are no described quality assurance mechanisms for newly formed stem cells. We observed intimate and specific interactions between macrophages and nascent blood stem cells in zebrafish embryos. Macrophage interactions frequently led to either removal of cytoplasmic material and stem cell division or complete engulfment and stem cell death. Stressed stem cells were marked by surface Calreticulin, which stimulated macrophage interactions. Using cellular barcoding, we found that Calreticulin knock-down or embryonic macrophage depletion reduced the number of stem cell clones that established adult hematopoiesis. Our work supports a model in which embryonic macrophages determine hematopoietic clonality by monitoring stem cell quality.
4 November 2021 in bioRxiv
The hematopoietic niche is a supportive microenvironment comprised of distinct cell types, including specialized vascular endothelial cells that directly interact with hematopoietic stem and progenitor cells (HSPCs). The molecular factors that specify niche endothelial cells and orchestrate HSPC homeostasis remain largely unknown. Using multi-dimensional gene expression and chromatin accessibility analyses, we define a conserved gene expression signature and cis -regulatory landscape unique to sinusoidal endothelial cells in the HSPC niche. Using enhancer mutagenesis and transcription factor overexpression, we elucidate a transcriptional code involving members of the Ets, Sox and Nuclear Hormone Receptor families that is sufficient to induce ectopic niche endothelial cells that associate with mesenchymal stromal cells and support the recruitment, maintenance and division of HSPCs in vivo . These studies set forth an approach for generating synthetic HSPC niches, in vitro or in vivo , and for effective therapies to modulate the endogenous niche.
23 June 2026 in Blood Advances
Sickle cell disease (SCD), caused by a point mutation in the β-globin gene (HBB), results in the production of sickle hemoglobin (HbS). Deoxy-HbS polymerizes, deforming red blood cells (RBCs) and leading to a cascade of clinical complications, including vaso-occlusion, hemolysis, inflammation, and progressive organ damage. An effective strategy to mitigate disease severity is the reactivation of fetal hemoglobin (HbF), which interferes with HbS polymerization. We explored the therapeutic potential of ZLN005, a small-molecule activator of the transcriptional coactivator PGC-1α (peroxisome proliferator–activated receptor gamma coactivator 1-α), by evaluating its impact on HbF induction in CD34+ hematopoietic progenitor cells derived from patients with SCD, in β-YAC transgenic mice carrying a normal human HBB cluster, and in SCD mice. ZLN005 increased γ-globin expression and HbF+ cells without impairing erythroid differentiation of CD34+ cells. Oral administration of ZLN005 to SCD mice increased HbF+ cells, reduced sickled RBCs, increased hemoglobin levels, lowered reticulocyte counts, and decreased spleen and liver pathology related to SCD. ZLN005 or related compounds could represent a promising new class of orally available HbF-inducing therapeutics.